MedTrace Logo

Feature Assessment Study for Indications Based Programming

NCT00711893 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 301

Last updated 2017-02-23

No results posted yet for this study

Summary

The purpose of this evaluation is to assess the acceptance level of specific programming recommendations based on the patient's clinical needs and primary indications when using the feature 'Indications Based Programming' (IBP) available in the ZOOMVIEW Software Application for the TELIGEN DR / VR and COGNIS family of devices compared to daily life programming chosen by physicians.

Conditions

  • Ventricular Tachycardia
  • Ventricular Flutter
  • Ventricular Fibrillation
  • Heart Failure

Interventions

DEVICE

Cognis 100-D, Teligen DR and VR 100 HE

Teligen is an implantable defibrillator for detection and termination of life threatening arrhythmias. Cognis includes in addition to these capabilities cardiac resynchronization therapy for patients having heart failure.

Sponsors & Collaborators

  • Guidant Corporation

    collaborator INDUSTRY

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Konrad Goehl, MD · Klinikum Nuernberg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • Austria
  • Belgium
  • China
  • France
  • Germany
  • Greece
  • Latvia
  • Netherlands
  • Slovakia
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00711893 on ClinicalTrials.gov